December 2023

(r)Alpha Lipoic Acid Is A Safe, Effective Pharmacologic Therapy Of Chronic Orthostatic Hypotension Associated With Low Sympathetic Tone

Leave a Comment / Articles /

Chronic orthostatic hypotension (OH), affecting 10 to 30% of the elderly, is associated with falls, and increased morbidity and mortality. Current pharmacologic therapy can cause or worsen hypertension and fluid retention. (r)α lipoic acid (ALA), a powerful natural antioxidant, avoids those complications and may assist management of chronic neurogenic orthostatic hypotension (NOH). The purpose of […]

(r)Alpha Lipoic Acid Is A Safe, Effective Pharmacologic Therapy Of Chronic Orthostatic Hypotension Associated With Low Sympathetic Tone Read More »

Differential Effects of Adrenergic Antagonists (Carvedilol vs. Metoprolol) on Parasympathetic and Sympathetic Activity: A Comparison of Measures 2 of 2

Leave a Comment / Articles /

BACKGROUND  Cardiovascular autonomic neuropathy (CAN) is recognized as a significant health risk, correlating with risk of heart disease, silent myocardial ischemia or sudden cardiac death. Beta-blockers are often prescribed to minimize risk.  OBJECTIVES  In this second of two articles, the effects on parasympathetic and sympathetic activity of the alpha/beta-adrenergic blocker, Carvedilol, are compared with those

Differential Effects of Adrenergic Antagonists (Carvedilol vs. Metoprolol) on Parasympathetic and Sympathetic Activity: A Comparison of Measures 2 of 2 Read More »

Differential Effects of Adrenergic Antagonists (Carvedilol vs. Metoprolol) on Parasympathetic and Sympathetic Activity: A Comparison of Measures 1 of 2

Leave a Comment / Articles /

BACKGROUND  Cardiovascular autonomic neuropathy (CAN) is recognized as a significant health risk. Specific and sensitive measures of CAN are needed for early identification and treatment to avoid complications, preferably in the preclinical state.  OBJECTIVES  In this first of two articles, the patient cohort is described and two measures of autonomic function are reviewed: the traditional

Differential Effects of Adrenergic Antagonists (Carvedilol vs. Metoprolol) on Parasympathetic and Sympathetic Activity: A Comparison of Measures 1 of 2 Read More »

Ranolazine Therapy Reduces Non-ST-Segment-Elevation Myocardial Infarction and Unstable Angina in Coronary Disease Patients with Angina

Leave a Comment / Articles /

Abstract High sympathetic tone and cardiac autonomic neuropathy (CAN) are associated with major adverse cardiac events (MACE). We have shown ranolazine (RAN) improves autonomic function. RAN was introduced to 51 successive anginal CD patients (RANCD). A control group of 54 successive nonanginal CD patients (NORANCD) continued baseline therapy. Mean study duration was 6.1 years, which

Ranolazine Therapy Reduces Non-ST-Segment-Elevation Myocardial Infarction and Unstable Angina in Coronary Disease Patients with Angina Read More »

Ranolazine Preserves And Improves Left Ventricular Ejection Fraction And Autonomic Measures When Added To Guideline-Driven Therapy In Chronic Heart Failure

Leave a Comment / Articles /

Background Ranolazine (RAN) reduces cardiac sodium channel 1.5’s late sodium current in congestive heart failure (CHF), reducing myocardial calcium overload, potentially improving left ventricular (LV) function. RAN blocks neuronal sodium channel 1.7, potentially altering parasympathetic and sympathetic (P&S) activity. The effects of RAN on LV ejection fraction (LVEF) and P&S function in CHF were studied.

Ranolazine Preserves And Improves Left Ventricular Ejection Fraction And Autonomic Measures When Added To Guideline-Driven Therapy In Chronic Heart Failure Read More »

Ranolazine Improves Autonomic Balance In Heart Failure When Added To Guideline-Driven Therapy

Leave a Comment / Articles /

Background The effect of ranolazine (RAN) on cardiac autonomic balance in congestive heart failure (CHF) was studied. Methods Fifty-four CHF patients were randomized to (1) open-label RAN (RANCHF) added to usual therapy vs. (2) usual therapy (NORANCHF). Parasympathetic and sympathetic (P&S) measurements were taken at baseline and at 12 months. Results A total of 16/27

Ranolazine Improves Autonomic Balance In Heart Failure When Added To Guideline-Driven Therapy Read More »

Routine Measurements of Cardiac Parasympathetic and Sympathetic Nervous Systems Assists in Primary and Secondary Risk Stratification and Management of Cardiovascular Clinic Patients

Leave a Comment / Articles /

Abstract    Objective To review our studies of the ease and importance of Parasympathetic and Sympathetic (P&S) measures in managing cardiovascular patients.  Background The autonomic nervous system is responsible for the development or progression of Hypertension (HTN), orthostasis, Coronary Disease (CAD), Congestive Heart Failure (CHF) and arrhythmias. Finally, new technology provides us with rapid, accurate

Routine Measurements of Cardiac Parasympathetic and Sympathetic Nervous Systems Assists in Primary and Secondary Risk Stratification and Management of Cardiovascular Clinic Patients Read More »

Autonomic Mechanisms and Therapeutic Implications of Postural Diabetic Cardiovascular Abnormalities

Leave a Comment / Articles /

Abstract Background Cardiovascular autonomic neuropathy (CAN) is a disorder of progressive autonomic dysfunction (AD) associated with diabetes and other chronic diseases. Orthostatic hypotension (OH) is one of the most incapacitating symptoms of CAN and AD. AD in OH can include sympathetic withdrawal (SW). To detect and diagnose SW, parasympathetic and sympathetic changes must be clearly

Autonomic Mechanisms and Therapeutic Implications of Postural Diabetic Cardiovascular Abnormalities Read More »

PAGES

FORMS

RESOURCES

Sign Up For Our Newsletter

Physio PS © 2024 All Rights Reserved. The material and information provided by Physio PS is for general information purposes only. You should not rely upon this material or information for basis of making healthcare, treatment, or diagnosis decisions. While Physio PS strives to provide the most correct and up-to-date information and data, Physio PS makes no representations or warranties of any kind, expressed or implied, about the completeness, accuracy, reliability, suitability, or availability with respect to the information, products, services, or related graphics contained. Any reliance placed on such material is therefore strictly at your own risk. Reporting Information is supplied under license by NCRC LLC. * ‘RFa’ is known to be a measure of Parasympathetic activity and ‘LFa’ is known to be a measure of Sympathetic activity, based on reference: Colombo J, Arora RR, DePace NL, Vinik AI, Clinical Autonomic Dysfunction: Measurement, Indications, Therapies, and Outcomes. Springer Science + Business Media, New York, NY; 2014.

Scroll to Top

Become An Authorized Distributor